PharmaPoint: Obesity – Global Drug Forecast and Market Analysis to 2022

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. These factors will be particularly true in the emerging markets where uptake of branded drugs will increase due to rapid economic growth.

Scope

Overview of Obesity, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized Obesity therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Obesity therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global Obesity therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The Obesity market is marked by the presence of several key unmet needs. What are these main unmet needs? Will the drugs under development fulfil these unmet needs? How do physicians and payers perceive these pipeline and currently marketed drugs?

Only one older generation drug with modest efficacy had been available until the recent arrival of two new therapies that could potentially change the prescribing landscape. Will these drugs make a significant impact on the Obesity market? Which drugs are used off-label for the treatment of obesity?

The diagnosed prevalence of Obesity in the world skyrocketed in the past 10 years and will continue increasing at a fast pace. How will epidemiological changes impact the growth of the future market? How does the burden of comorbidities associated with overweight and obesity impact the treatment algorithm?

Companies mentioned

Allergan

Apollo Endosurgery, Inc

Arena Pharmaceuticals

Aspire Bariatrics, Inc.

Bariatric Solutions

Baronova

Cousin Biotech

CR Bard

Endalis Laboratory

EnteroMedics, Inc

GI Dynamics

IntraPace, Inc.

Medical ...

Allergan

Apollo Endosurgery, Inc

Arena Pharmaceuticals

Aspire Bariatrics, Inc.

Bariatric Solutions

Baronova

Cousin Biotech

CR Bard

Endalis Laboratory

EnteroMedics, Inc

GI Dynamics

IntraPace, Inc.

Medical Innovations

MetaCure Inc.

Novo Nordisk

Obalon Therapeutics

Orexigen Therapeutics

ReShape Medical

Roche

Shionogi & Co.

Spatz Medical

Takeda

Valentyx, Inc.

Vivus Inc.

+ More

Table of Contents

1Table of Contents1

1.1List of Tables11

1.2List of Figures20

2Executive Summary24

2.1Sales for Obesity Therapy Expected to Increase 2012–202225

2.2Companies ...

1Table of Contents1

1.1List of Tables11

1.2List of Figures20

2Executive Summary24

2.1Sales for Obesity Therapy Expected to Increase 2012–202225

2.2Companies Focus on Efficacy-Driven Solutions in the Revival of This Market26

2.3The Need for More Novel Therapies Defines the Obesity Market28

2.4Reimbursement and Disease Perception Are Long-Standing Barriers to Market Growth28

2.5More Efficacious Drugs Will Reinvigorate the Market29

2.6What Do the Physicians Think?30

3Introduction31

3.1Catalyst32

3.2Related Reports33

3.3Upcoming Related Reports33

4Disease Overview34

4.1Etiology and Pathophysiology36

4.1.1Etiology36

4.1.2Pathophysiology37

4.1.3Prognosis37

4.1.4Quality of Life37

4.2Symptoms38

5Epidemiology38

5.1Disease Overview38

5.2Risk Factors and Comorbidities40

5.2.1Family history is a strong predictor of obesity40

5.2.2Physical inactivity is an independent predictor of obesity41

5.2.3Excessive caloric intake doubles the risk for obesity42

5.2.4Hypertension is as high as 42% in obese adults42

5.2.5Dyslipidemia and type 2 diabetes are common comorbidities in obese patients44

5.3Global Trends46

5.3.1US47

5.3.25EU49

5.3.3Japan56

5.3.4Brazil57

5.3.5Canada60

5.4Forecast Methodology61

5.4.1Sources Used68

5.4.2Forecast Assumptions and Methods: Prevalent Cases of Overweight, Obesity, Obesity by Class, and Comorbidities75

5.4.3Sources Not Used92

5.5Epidemiology Forecast of Overweight (2012–2022)92

5.5.1Prevalent Cases of Overweight92

5.5.2Age-Specific Prevalent Cases of Overweight94

5.5.3Sex-Specific Prevalent Cases of Overweight96

5.5.4Age-Standardized Prevalence of Overweight99

5.6Epidemiology Forecast of Obesity (2012–2022)100

5.6.1Prevalent Cases of Obesity100

5.6.2Age-Specific Prevalent Cases of Obesity101

5.6.3Sex-Specific Prevalent Cases of Obesity103

5.6.4Age-Standardized Prevalence of Obesity106

5.7Epidemiology Forecast of Obesity Class I (2012–2022)107

5.7.1Prevalent Cases of Obesity Class I107

5.7.2Age-Specific Prevalent Cases of Obesity Class I108

5.7.3Sex-Specific Prevalent Cases of Obesity Class I110

5.7.4Age-Standardized Prevalence of Obesity Class I113

5.8Epidemiology Forecast of Obesity Class II (2012–2022)114

5.8.1Prevalent Cases of Obesity Class II114

5.8.2Age-Specific Prevalent Cases of Obesity Class II116

5.8.3Sex-Specific Prevalent Cases of Obesity Class II118

5.8.4Age-Standardized Prevalence of Obesity Class II121

5.9Epidemiology Forecast of Obesity Class III (2012–2022)122

5.9.1Prevalent Cases of Obesity Class III122

5.9.2Age-Specific Prevalent Cases of Obesity Class III124

5.9.3Sex-Specific Prevalent Cases of Obesity Class III126

5.9.4Age-Standardized Prevalence of Obesity Class III128

5.10Epidemiology Forecast of Comorbidities among Adults with Overweight/Obesity (2012 and 2022)130

5.10.1Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity130

5.10.2Prevalent Cases of Diagnosed Hypertension in Adults with Overweight/Obesity132

5.10.3Prevalent Cases of Dyslipidemia among Adults with Overweight/Obesity134

5.11Discussion136

5.11.1Conclusions on Epidemiological Trends136

5.11.2Limitations of the Analysis137

5.11.3Strengths of the Analysis137

6Disease Management139

6.1Treatment Overview139

6.2US145

6.2.1Diagnosis145

6.2.2Clinical Practice145

6.3France149

6.3.1Diagnosis149

6.3.2Clinical Practice151

6.4Germany153

6.4.1Diagnosis153

6.4.2Clinical Practice155

6.5Italy160

6.5.1Diagnosis160

6.5.2Clinical Practice163

6.6Spain165

6.6.1Diagnosis165

6.6.2Clinical Practice166

6.7UK167

6.7.1Diagnosis167

6.7.2Clinical Practice168

6.8Japan169

6.8.1Diagnosis169

6.8.2Clinical Practice170

6.9Brazil172

6.9.1Diagnosis172

6.9.2Clinical Practice174

6.10Canada177

6.10.1Diagnosis177

6.10.2Clinical Practice178

7Competitive Assessment180

7.1Overview180

7.2Strategic Competitor Assessment183

7.3Product Profiles: Drugs185

7.3.1Phentermine185

7.3.2Xenical (orlistat)192

7.3.3Qsymia (phentermine-topiramate)196

7.3.4Belviq (lorcaserin)203

7.3.5Topiramate209

7.3.6Oblean (cetilistat)213

7.4Product Profiles: Medical Devices – Artifical Fulness Devices217

7.4.1End Ball (Endalis Laboratory)220

7.4.2Obalon (Obalon Therapeutics)221

7.4.3Orbera (Allergan)224

7.4.4Heliosphere (Helioscopie)227

7.4.5ReShape Duo (ReShape Medical)230

7.4.6SatiSphere (EndoSphere)231

7.4.7Spatz 3 (Spatz Medical)233

7.5Product Profiles: Medical Devices – Endoscopic Surgical Devices237

7.5.1Intraluminal Circular Stapler (Ethicon)238

7.5.2OverStitch (Apollo Endosurgery)239

7.5.3StomaphyX (EndoGastric Solutions)242

7.6Product Profiles: Medical Devices – Gastric Electrical Stimulation245

7.6.1Abiliti (IntraPace)247

7.6.2DIAMOND Tantalus (MetaCure)250

7.7Product Profiles: Medical Devices – Malabsorption Devices252

7.7.1EndoBarrier (GI Dynamics)253

7.8Product Profiles: Medical Devices – Neuronal Blocking Technology255

7.8.1Vbloc Maestro System (EnteroMedics)255

7.9Product Profiles: Medical Devices – Restrictive Devices257

7.9.1AMI Band (Agency for Medical Innovations)259

7.9.2Bioring (Cousin Biotech)261

7.9.3Heliogast (Helioscopie)264

7.9.4Lap-Band (Allergan)267

7.9.5Midband (Medical Innovation Development)270

7.9.6MiniMizer Extra (Bariatric Solutions)273

7.9.7Swedish/Realize Band (Ethicon Endo-Surgery)276

8Opportunity and Unmet Need279

8.1Overview279

8.2A Drug with Greater Than 10% Average Weight Loss280

8.2.1Unmet Need280

8.2.2Gap Analysis281

8.2.3Opportunity282

8.3A Drug with Increased Safety and Tolerability282

8.3.1Unmet Need282

8.3.2Gap Analysis283

8.3.3Opportunity283

8.4Reimbursement by Private and Public Payers284

8.4.1Unmet Need284

8.4.2Gap Analysis286

8.4.3Opportunity286

8.5Increased Physician Education287

8.5.1Unmet Need287

8.5.2Gap Analysis287

8.5.3Opportunity288

8.6Increased Drug-Treatment Rate288

8.6.1Unmet Need288

8.6.2Gap Analysis289

8.6.3Opportunity289

8.7Improved Guidelines290

8.7.1Unmet Need290

8.7.2Gap Analysis291

8.7.3Opportunity291

8.8Improved Approach to Diagnosis292

8.8.1Unmet Need292

8.8.2Gap Analysis292

8.8.3Opportunity292

9Pipeline Assessment293

9.1Overview293

9.2Clinical Trial Mapping296

9.2.1Clinical Trials by Country296

9.3Clinical Trials by Phase and Trial Status297

9.4Promising Drugs in Clinical Development298

9.4.1Contrave301

9.4.2Victoza (liraglutide)307

9.4.3Velneperit314

9.4.4Empatic318

9.4.5Promising Early-Stage Pharmacological Approaches324

9.5Artificial Fullness Devices328

9.5.1Full Sense Device (BFKW)328

9.5.2TransPyloric Shuttle (Baronova)329

9.6Promising Deep-Brain Stimulation Devices in Development331

9.6.1Deep Brain Stimulation331

9.6.2Deep Brain Stimulation Device (NeuroSigma)332

9.7Promising Endoscopic Surgical Devices334

9.7.1ACE Stapler (BaroSense)334

9.7.2RS2 Restore (C.R. Bard)335

9.8Promising Malabsorption Devices in Development337

9.8.1ValenTx (ValenTx)337

9.9Promising Restrictive Devices in Development339

9.9.1AMI B-Band (Agency for Medical Innovations)339

9.9.2AMI Basket (AMI)341

9.9.3TERIS (BaroSense)343

10Current and Future Players345

10.1Overview345

10.1.1Medical Device Companies Have the Opportunity to Incorporate Lifestyle Programs347

10.2Trends in Corporate Strategy350

10.3Company Profiles: Pharmaceutical and Biotech Companies351

10.3.1Orexigen Therapeutics351

10.3.2Novo Nordisk355

10.3.3Takeda Pharmaceutical Company357

10.3.4Shionogi359

10.3.5Roche Holdings360

10.3.6Vivus362

10.3.7Arena Pharmaceuticals and Eisai366

10.4Company Profiles: Device Companies369

10.4.1Allergan369

10.4.2Apollo Endosurgery372

10.4.3Aspire Bariatrics374

10.4.4Agency for Medical Innovation375

10.4.5Bariatric Solutions376

10.4.6Baronova377

10.4.7BaroSense379

10.4.8BFKW380

10.4.9Cousin Biotech381

10.4.10C.R. Bard383

10.4.11Endalis Laboratory384

10.4.12EndoGastric Solutions385

10.4.13EndoSphere387

10.4.14EnteroMedics388

10.4.15Ethicon Endo-Surgery389

10.4.16GI Dynamics391

10.4.17Helioscopie392

10.4.18IntraPace393

10.4.19Medical Innovation Development395

10.4.20MetaCure397

10.4.21Obalon Therapeutics398

10.4.22ReShape Medical399

10.4.23Spatz Medical400

10.4.24ValenTx401

11Market Outlook403

11.1Global Markets405

11.1.1Forecast405

11.1.2Drivers and Barriers – Global Issues407

11.2United States414

11.2.1Forecast414

11.2.2Key Events417

11.2.3Drivers and Barriers418

11.3France422

11.3.1Forecast422

11.3.2Key Events425

11.3.3Drivers and Barriers426

11.4Germany428

11.4.1Forecast428

11.4.2Key Events432

11.4.3Drivers and Barriers433

11.5Italy435

11.5.1Forecast435

11.5.2Key Events439

11.5.3Drivers and Barriers440

11.6Spain442

11.6.1Forecast442

11.6.2Key Events445

11.6.3Drivers and Barriers446

11.7United Kingdom448

11.7.1Forecast448

11.7.2Key Events451

11.7.3Drivers and Barriers451

11.8Japan454

11.8.1Forecast454

11.8.2Key Events457

11.8.3Drivers and Barriers458

11.9Brazil460

11.9.1Forecast460

11.9.2Key Events464

11.9.3Drivers and Barriers464

11.10Canada466

11.10.1Forecast466

11.10.2Key Events469

11.10.3Drivers and Barriers470

12Appendix472

12.1Bibliography472

12.2Abbreviations494

12.3Research Methodology499

12.4Forecasting Methodology500

12.4.1Percent Drug-Treated Obesity Patients501

12.4.2Drugs Included in Each Therapeutic Class501

12.4.3Launch and Patent Expiry Dates501

12.4.4General Pricing Assumptions502

12.4.5Individual Drug Assumptions503

12.4.6Generic Erosion507

12.4.7Pricing of Pipeline Agents507

12.5Physicians, Specialists, and Payers Included in This Study507

12.6About the Authors511

12.6.1Analysts511

12.6.2Therapy Director – CVMD and Infectious Disease511

12.6.3Director – Medical Devices512

12.6.4Epidemiologist512

12.6.5Global Head of Healthcare513

12.7About GlobalData513

12.8Contact Us514

12.9Disclaimer514

List of Tables

Table 1:Obesity: Key Metrics in the Nine Major Pharmaceutical Markets24

Table 2:Target Pathways in the Treatment of Obesity37

Table 3:Symptoms of Obesity38 ...

Table 1:Obesity: Key Metrics in the Nine Major Pharmaceutical Markets24

Table 2:Target Pathways in the Treatment of Obesity37

Table 3:Symptoms of Obesity38

Table 4:The WHO Classification System of Adult Overweight and Obesity According to BMI39

Table 5: Risk Factors and Comorbidities of Obesity40

Table 6: 9MM, Age-Adjusted and Crude Prevalence (%) of Obesity, by Sex, Ages = 20 Years, 200846

Table 7: JASSO and WHO Classifications of Obesity56

Table 8: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Overweight62

Table 9: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Obesity63

Table 10:Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Obesity Class I, Class II, and Class III64

Table 11: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Comorbidities in Overweight/Obese66

Table 12: 9MM, Prevalent Cases of Overweight, Ages = 18 Years, Both Sexes, N (Millions), 2012–202293

Table 13: 9MM, Prevalent Cases of Overweight, by Age, Both Sexes, N (Millions), Row (%), 201295

Table 14: 9MM, Prevalent Cases of Overweight, Ages = 18 Years, by Sex, N (Millions), Row (%), 201297

Table 15: 9MM, Prevalent Cases of Obesity, Ages = 18 Years, Both Sexes, N (Millions), 2012–2022100

Table 16: 9MM, Prevalent Cases of Obesity, by Age, Both Sexes, N (Millions), Row (%), 2012102

Table 17: 9MM, Prevalent Cases of Obesity, Ages = 18 Years, by Sex, N (Millions), Row (%), 2012104

Table 18:9MM, Prevalent Cases of Obesity Class I, Ages = 18 Years, Both Sexes, N (Millions), 2012–2022107

Table 19: 9MM, Prevalent Cases of Obesity Class I, by Age, Both Sexes, N (Millions), Row (%), 2012109

Table 20: 9MM, Prevalent Cases of Obesity Class I, Ages = 18 Years, by Sex, N (Millions), Row (%), 2012111

Table 21: 9MM, Prevalent Cases of Obesity Class II, Ages = 18 Years, Both Sexes, N (Millions), 2012–2022114

Table 22: 9MM, Prevalent Cases of Obesity Class II, by Age, Both Sexes, N (Millions), Row (%), 2012117

Table 23: 9MM, Prevalent Cases of Obesity Class II, Ages = 18 Years, by Sex, N (Millions), Row (%), 2012119

Table 24: 9MM, Prevalent Cases of Obesity Class III, Ages = 18 Years, Both Sexes, N (Millions), 2012–2022122

Table 25:9MM, Prevalent Cases of Obesity Class III, by Age, Both Sexes, N (Millions), Row (%), 2012125

Table 26: 9MM, Prevalent Cases of Obesity Class III, Ages = 18 Years, by Sex, N (Millions), Row (%), 2012126

Table 27: 5MM*, Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022130

Table 28: 6MM*, Prevalent Cases of Diagnosed Hypertension among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022132

Table 29: 4MM, Prevalent Cases of Dyslipidemia* among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022134

Table 30: Treatment Guidelines for Obesity142

Table 31: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013142

Table 32: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk144

Table 33: Brazilian Classification of Overweight and Obesity172

Table 34:Bariatric Treatment Attributes183

Table 35: Leading Drug Treatments for Obesity, 2013183

Table 36: Marketed Obesity Treatment Devices by Type185

Table 37: Product Profile – Phentermine187

Table 38: Phentermine SWOT Analysis, 2013189

Table 39: Global Sales Forecasts ($m) for Phentermine, 2012–2022191

Table 40: Global Sales Forecasts ($m) for Phentermine + Topiramate, 2012–2022191

Table 41: Product Profile – Xenical192

Table 42: Xenical SWOT Analysis, 2013194

Table 43: Global Sales Forecasts ($m) for Xenical, 2012–2022196

Table 44: Product Profile – Qsymia198

Table 45: Qsymia SWOT Analysis, 2013201

Table 46: Global Sales Forecasts ($m) for Qsymia, 2012–2022203

Table 47: Product Profile – Belviq206

Table 48: Belviq SWOT Analysis, 2013207

Table 49: Global Sales Forecasts ($m) for Belviq, 2012–2022209

Table 50: Product Profile – Topiramate210

Table 51: Topiramate SWOT Analysis, 2013213

Table 52: Product Profile – Oblean214

Table 53: ObleanSWOT Analysis, 2013215

Table 54: Global Sales Forecasts ($m) for Oblean, 2012–2022216

Table 55: Product Profile – End Ball220

Table 56: End Ball SWOT Analysis221

Table 57: Product Profile – Obalon222

Table 58: Obalon SWOT Analysis223

Table 59: Product Profile – Orbera225

Table 60: Orbera SWOT Analysis226

Table 61: Product Profile – Heliosphere227

Table 62:Heliosphere SWOT Analysis229

Table 63: Product Profile – ReShape Duo230

Table 64: ReShape Duo SWOT Analysis231

Table 65: Product Profile – SatiSphere232

Table 66: SatiSphere SWOT Analysis232

Table 67: Product Profile – Spatz234

Table 68: Spatz SWOT Analysis236

Table 69:Product Profile – Intraluminal Circular Stapler238

Table 70: Intraluminal Circular Stapler SWOT Analysis239

Table 71: Product Profile – OverStitch240

Table 72: OverStitch SWOT Analysis241

Table 73: Product Profile – StomaphyX243

Table 74: StomaphyX SWOT Analysis244

Table 75: Product Profile – Abiliti247

Table 76: Abiliti SWOT Analysis249

Table 77: Product Profile – DIAMOND Tantalus250

Table 78: DIAMOND Tantalus SWOT Analysis252

Table 79: Product Profile – EndoBarrier253

Table 80: EndoBarrier SWOT Analysis255

Table 81: Product Profile – Vbloc Maestro System255

Table 82: Vbloc Maestro System SWOT Analysis256

Table 83: Product Profile – AMI Band259

Table 84: AMI Band SWOT Analysis260

Table 85: Product Profile – Bioring262

Table 86: Bioring SWOT Analysis263

Table 87: Product Profile – Heliogast265

Table 88: Heliogast SWOT Analysis266

Table 89:Product Profile – Lap-Band267

Table 90: Lap-Band SWOT Analysis270

Table 91:Product Profile – Midband271

Table 92:SWOT Analysis272

Table 93: Product Profile – MiniMizer Extra273

Table 94:SWOT Analysis275

Table 95: Product Profile – Swedish/Realize Band276

Table 96: Swedish/Realize Band SWOT Analysis278

Table 97: Unmet Need and Opportunity in Obesity279

Table 98: Endpoint Analysis of Clinical Trials Conducted in Obesity, 2013295

Table 99: Obesity– Clinical Trials by Phase and Trial Status, 2012297

Table 100: Obesity – Phase II–III Pipeline, 2013298

Table 101: Comparison of Therapeutic Classes in Development for Obesity, 2013301

Table 102: Obesity Treatment Pipeline Devices by Type301

Table 103: Product Profile – Contrave303

Table 104: Contrave SWOT Analysis, 2013306

Table 105: Global Sales Forecasts ($m) for Contrave, 2012–2022306

Table 106: Product Profile – Victoza309

Table 107: Victoza SWOT Analysis, 2013312

Table 108: Global Sales Forecasts ($m) for Victoza, 2012–2022313

Table 109: Product Profile – Velneperit314

Table 110: Velneperit SWOT Analysis, 2013317

Table 111: Global Sales Forecasts ($m) for Velneperit, 2012–2022317

Table 112: Product Profile – Empatic320

Table 113: Empatic SWOT Analysis, 2013322

Table 114: Global Sales Forecasts ($m) for Empatic, 2012–2022323

Table 115: Obesity – Promising Early-Stage Approaches, 2013324

Table 116:Product Profile – Full Sense Device328

Table 117:Full Sense Device SWOT Analysis329

Table 118:Product Profile – TransPyloric Shuttle330

Table 119:TransPyloric Shuttle SWOT Analysis331

Table 120:Product Profile – Deep Brain Stimulation Device332

Table 121: Deep Brain Stimulation Device SWOT Analysis333

Table 122:Product Profile – ACE Stapler334

Table 123:ACE Stapler SWOT Analysis334

Table 124:Product Profile – RS2 Restore335

Table 125:RS2 Restore SWOT Analysis336

Table 126:Product Profile – ValenTx338

Table 127:ValenTx SWOT Analysis339

Table 128:Product Profile – AMI B-Band339

Table 129:AMI B-Band SWOT Analysis340

Table 130:Product Profile – AMI Basket341

Table 131:AMI Basket SWOT Analysis342

Table 132:Product Profile – TERIS343

Table 133:TERIS SWOT Analysis344

Table 134: Key Companies in the Obesity Market, 2013349

Table 135: Orexigen’s Disease/Therapy Portfolio Assessment, 2013354

Table 136: Orexigen Therapeutics SWOT Analysis, 2013354

Table 137: Novo Nordisk’s Disease/Therapy Portfolio Assessment, 2013356

Table 138: Novo Nordisk SWOT Analysis, 2013357

Table 139: Takeda’s Disease / Therapy Portfolio Assessment, 2013358

Table 140: Takeda SWOT Analysis, 2013358

Table 141: Shionogi’s Disease/Therapy Portfolio Assessment, 2013360

Table 142: Shionogi SWOT Analysis, 2013360

Table 143: Roche Holding’s Disease/Therapy Portfolio Assessment, 2013361

Table 144: Roche Holdings SWOT Analysis, 2013362

Table 145: Vivus’ Disease/Therapy Portfolio Assessment, 2013366

Table 146: Vivus SWOT Analysis, 2013366

Table 147: Arena Pharmaceuticals’ Disease/Therapy Portfolio Assessment, 2013369

Table 148: Arena and Eisai SWOT Analysis, 2013369

Table 149:Company Profile – Allergan371

Table 150:Allergan SWOT Analysis372

Table 151:Company Profile – Apollo Endosurgery373

Table 152:Apollo Endosurgery SWOT Analysis373

Table 153:Company Profile – Aspire Bariatrics374

Table 154: Aspire Bariatrics SWOT Analysis375

Table 155: Company Profile – AMI375

Table 156: AMI SWOT Analysis376

Table 157: Company Profile – Bariatric Solutions376

Table 158: Bariatric Solutions SWOT Analysis377

Table 159: Company Profile – Baronova377

Table 160: Baronova SWOT Analysis378

Table 161: Company Profile – BaroSense379

Table 162: BaroSense SWOT Analysis380

Table 163: Company Profile – BFKW380

Table 164: BFKW SWOT Analysis381

Table 165: Company Profile – Cousin Biotech381

Table 166: Cousin Biotech SWOT Analysis382

Table 167: Company Profile – CR Bard383

Table 168: CR Bard SWOT Analysis384

Table 169: Company Profile – Endalis Laboratory384

Table 170: Endalis Laboratory SWOT Analysis385

Table 171: Company Profile – EndoGastric Solutions385

Table 172: EndoGastric Solutions SWOT Analysis386

Table 173: Company Profile – EndoSphere387

Table 174: EndoSphere SWOT Analysis387

Table 175: Company Profile – EnteroMedics388

Table 176: EnteroMedics SWOT Analysis389

Table 177: Company Profile – Ethicon Endo-Surgery389

Table 178: Ethicon Endo-Surgery SWOT Analysis390

Table 179: Company Profile – GI Dynamics391

Table 180: GI Dynamics SWOT Analysis392

Table 181: Company Profile – Helioscopie392

Table 182: Helioscopie SWOT Analysis393

Table 183: Company Profile – IntraPace393

Table 184: IntraPace SWOT Analysis394

Table 185: Company Profile – Medical Innovation Development395

Table 186: Medical Innovation Development SWOT Analysis396

Table 187: Company Profile – MetaCure397

Table 188: MetaCure SWOT Analysis397

Table 189: Company Profile – Obalon Therapeutics398

Table 190: Obalon Therapeutics SWOT Analysis399

Table 191: Company Profile – ReShape Medical400

Table 192: ReShape Medical SWOT Analysis400

Table 193: Company Profile – Spatz Medical401

Table 194: Spatz Medical SWOT Analysis401

Table 195: Company Profile – ValenTx401

Table 196: ValenTx SWOT Analysis402

Table 197: Global Sales Forecasts ($m) for Obesity, 2012-2022405

Table 198: Global Obesity Market – Drivers and Barriers, 2012–2012407

Table 199: Sales Forecasts ($) for Obesity in the United States, 2012–2022416

Table 200: Key Events Impacting Sales for Obesity in the United States, 2012–2022418

Table 201: Obesity Market in the United States – Drivers and Barriers, 2012–2022418

Table 202:Sales Forecasts ($) for Obesity in France, 2012–2022424

Table 203: Key Events Impacting Sales for Obesity in France, 2012–2022426

Table 204: Obesity Market in France – Drivers and Barriers, 2012–2022426

Table 205: Sales Forecasts ($) for Obesity in Germany, 2012–2022431

Table 206: Key Events Impacting Sales for Obesity in Germany, 2012–2022433

Table 207: Obesity Market in Germany – Drivers and Barriers, 2012–2022433

Table 208: Sales Forecasts ($) for Obesity in Italy, 2012–2022438

Table 209: Key Events Impacting Sales for Obesity in Italy, 2012–2022440

Table 210: Obesity Market in Italy – Drivers and Barriers, 2012–2022440

Table 211: Sales Forecasts ($) for Obesity in Spain, 2012–2022444

Table 212: Key Events Impacting Sales for Obesity in Spain, 2012–2022446

Table 213: Obesity Market in Spain – Drivers and Barriers, 2012–2022446

Table 214: Sales Forecasts ($) for Obesity in United Kingdom, 2012–2022449

Table 215: Key Events Impacting Sales for Obesity in the United Kingdom, 2012–2022451

Table 216: Obesity Market in the United Kingdom – Drivers and Barriers, 2012–2022451

Table 217: Sales Forecasts ($) for Obesity in Japan, 2012–2022456

Table 218:Events Impacting Sales for Obesity in Japan, 2012–2022458

Table 219: Obesity Market in Japan – Drivers and Barriers, 2012–2022458

Table 220: Sales Forecasts ($) for Obesity in Brazil, 2012–2022462

Table 221:Key Events Impacting Sales for Obesity in Brazil, 2012–2022464

Table 222: Obesity Market in Brazil – Drivers and Barriers, 2012–2022464

Table 223: Sales Forecasts ($) for Obesity in Canada, 2012–2022468

Table 224:Events Impacting Sales for Obesity in Canada, 2012–2022470

Table 225: Obesity Market in Canada – Drivers and Barriers, 2012–2022470

Table 226: Key Launch Dates501

Table 227: Key Patent Expiries502

List of Figures

Figure 1: Total: Global Sales for Obesity by Region, 2012–202226

Figure 2: Company Portfolio Gap Analysis in Obesity, 2012–202227

Figure 3: Competitive Assessment ...

Figure 1: Total: Global Sales for Obesity by Region, 2012–202226

Figure 2: Company Portfolio Gap Analysis in Obesity, 2012–202227

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012–202229

Figure 4: US, Overweight and Obesity Age-Adjusted Prevalence (%), Ages 20–74 Years, Men, 1960–201048

Figure 5: US, Overweight and Obesity Age-Adjusted Prevalence (%), Ages 20–74 Years, Women, 1960–201049

Figure 6: France, Overweight and Obesity Prevalence (%), Ages = 15 Years, Men, 1997–200651

Figure 7: France, Overweight and Obesity Prevalence (%), Ages = 15 Years, Women, 1997–200651

Figure 8: Italy, Overweight and Obesity Prevalence (%), Ages = 18, Men, 1983–201053

Figure 9: Italy, Overweight and Obesity Prevalence (%), Ages = 18, Men, 1983–201053

Figure 10: UK, Overweight and Obesity Prevalence (%), Ages = 16 Years, Men, 1993–201155

Figure 11: UK, Overweight and Obesity Prevalence (%), Ages = 16 Years, Women, 1993–201155

Figure 12: Japan, Obesity Prevalence (%), Ages = 20 Years, by Sex, 1976–200657

Figure 13: Brazil, Overweight and Obesity Prevalence (%), Ages = 20 Years, Men, 1975–200358

Figure 14: Brazil, Overweight and Obesity Prevalence (%), Ages = 20 Years, Women, 1975–200359

Figure 15: Canada, Obesity Prevalence (%), Ages = 18 Years, Both Sexes, 1978–200860

Figure 16:9MM, Prevalent Cases of Overweight, Ages = 18 Years, Both Sexes, N (Millions), 2012–202294

Figure 17: 9MM, Prevalent Cases of Overweight, by Age, Both Sexes, N (Millions), 201296

Figure 18: 9MM, Prevalent Cases of Overweight, Ages = 18 Years, by Sex, N (Millions), 201298

Figure 19: 9MM, Overweight Age-Standardized Prevalence (%), Ages = 18 Years, by Sex, 201299

Figure 20: 9MM, Prevalent Cases of Obesity, Ages = 18 Years, Both Sexes, N (Millions), 2012–2022101

Figure 21: 9MM, Prevalent Cases of Obesity, by Age, Both Sexes, N (Millions), 2012103

Figure 22: 9MM, Prevalent Cases of Obesity, Ages = 18 Years, by Sex, N (Millions), 2012105

Figure 23: 9MM, Obesity Age-Standardized Prevalence (%), Ages = 18 Years, by Sex, 2012106

Figure 24: 9MM*, Prevalent Cases of Obesity Class I, Ages = 18 Years, Both Sexes, N (Millions), 2012–2022108

Figure 25: 9MM*, Prevalent Cases of Obesity Class I, by Age, Both Sexes, N (Millions), 2012110

Figure 26: 9MM*, Prevalent Cases of Obesity Class I, Ages = 18 Years, by Sex, N (Millions), 2012112

Figure 27: 9MM*, Obesity Class I Age-Standardized Prevalence (%), Ages = 18 Years, by Sex, 2012113

Figure 28: 9MM*, Prevalent Cases of Obesity Class II, Ages = 18 Years, Both Sexes, N (Millions), 2012–2022115

Figure 29: 9MM*, Prevalent Cases of Obesity Class II, by Age, Both Sexes, N (Millions), 2012118

Figure 30: 9MM*, Prevalent Cases of Obesity Class II, Ages = 18 Years, by Sex, N (Millions), 2012120

Figure 31: 9MM*, Age-Standardized Prevalence (%) of Obesity Class II, Ages = 18 Years, by Sex, 2012121

Figure 32: 9MM*, Prevalent Cases of Obesity Class III, Ages = 18 Years, Both Sexes, N (Millions), 2012–2022123

Figure 33: 9MM*, Prevalent Cases of Obesity Class III, by Age, Both Sexes, N (Millions), 2012126

Figure 34: 9MM*, Prevalent Cases of Obesity Class III, Ages = 18 Years, by Sex, N (Millions), 2012127

Figure 35: 9MM*, Obesity Class III Age-Standardized Prevalence (%), Ages = 18 Years, by Sex, 2012129

Figure 36: 5MM*, Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012131

Figure 37: 6MM*, Prevalent Cases of Diagnosed Hypertension among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012133

Figure 38: 4MM*, Prevalent Cases of Dyslipidemia** among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012135

Figure 39: Treatment Algorithm for Obesity141

Figure 40: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in the United States, 2012–2022145

Figure 41: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in France, 2012–2022151

Figure 42: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Germany, 2012–2022155

Figure 43: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Italy, 2012–2022162

Figure 44: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Spain, 2012–2022166

Figure 45: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in the United Kingdom, 2012–2022168

Figure 46: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Japan, 2012–2022170

Figure 47: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Brazil, 2012–2022173

Figure 48: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Canada, 2012–2022178

Figure 49: Obesity Therapeutics – Clinical Trials by Country, 2012297

Figure 50: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012–2022300

Figure 51: Company Portfolio Gap Analysis in Obesity, 2012–2022350

Figure 52: Global Sales for Obesity by Region, 2012–2022406

Figure 53: Sales for Obesity in the United States by Drug Class, 2012–2022417

Figure 54: Sales for Obesity in France by Drug Class, 2012–2022425

Figure 55: Sales for Obesity in Germany by Drug Class, 2012–2022432

Figure 56: Sales for Obesity in Italy by Drug Class, 2012–2022439

Figure 57:Sales for Obesity in Spain by Drug Class, 2012–2022445

Figure 58: Sales for Obesity in the United Kingdom by Drug Class, 2012–2022450

Figure 59: Sales for Obesity in Japan by Drug Class, 2012–2022457

Figure 60: Sales for Obesity in Brazil by Drug Class, 2012–2022463

Figure 61: Sales for Obesity in Canada by Drug Class, 2012–2022469

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports